A review of circulating tumor DNA in hepatobiliary malignancies

Kabir Mody, Sean P. Cleary

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Circulating tumor DNA (ctDNA) is released into circulation (blood) specifically from tumor cells undergoing metabolic secretion, apoptosis, or necrosis, carries tumor-specific genetic or epigenetic alterations. Technologies enabling clinical evaluation of ctDNA continue to advance rapidly and allow for the assessment of patient-specific tumoral genetic and epigenetic alterations. This holds great potential for earlier detection of disease, serial monitoring of tumor heterogeneity, identification of therapeutic targets, and evaluation of treatment response and mechanisms of resistance. Hepatobiliary malignancies are often diagnosed late, recur commonly, yield limited available tumor on biopsy, and harbor several genomic alterations with potential therapeutic impacts. Patients suffering from or at risk for these diseases thus stand to benefit immensely from this technology. Herein, we review the limited literature pertaining to the potential for ctDNA technologies in such patients. Patients with these cancers stand to benefit greatly from the application of ctDNA technologies, and concerted efforts at further investigation of such are ongoing and greatly needed.

Original languageEnglish (US)
Article number212
JournalFrontiers in Oncology
Volume8
Issue numberJUN
DOIs
StatePublished - Jun 11 2018

Fingerprint

DNA
Neoplasms
Technology
Epigenomics
Blood Circulation
Early Diagnosis
Necrosis
Therapeutics
Apoptosis
Biopsy

Keywords

  • Cholangiocarcinoma
  • Circulating tumor DNA
  • Hepatocellular carcinoma
  • Liver neoplasms/blood
  • Liver neoplasms/genetics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A review of circulating tumor DNA in hepatobiliary malignancies. / Mody, Kabir; Cleary, Sean P.

In: Frontiers in Oncology, Vol. 8, No. JUN, 212, 11.06.2018.

Research output: Contribution to journalReview article

Mody, Kabir ; Cleary, Sean P. / A review of circulating tumor DNA in hepatobiliary malignancies. In: Frontiers in Oncology. 2018 ; Vol. 8, No. JUN.
@article{7a6dc37b33514358a6f1c1c10d82bcb5,
title = "A review of circulating tumor DNA in hepatobiliary malignancies",
abstract = "Circulating tumor DNA (ctDNA) is released into circulation (blood) specifically from tumor cells undergoing metabolic secretion, apoptosis, or necrosis, carries tumor-specific genetic or epigenetic alterations. Technologies enabling clinical evaluation of ctDNA continue to advance rapidly and allow for the assessment of patient-specific tumoral genetic and epigenetic alterations. This holds great potential for earlier detection of disease, serial monitoring of tumor heterogeneity, identification of therapeutic targets, and evaluation of treatment response and mechanisms of resistance. Hepatobiliary malignancies are often diagnosed late, recur commonly, yield limited available tumor on biopsy, and harbor several genomic alterations with potential therapeutic impacts. Patients suffering from or at risk for these diseases thus stand to benefit immensely from this technology. Herein, we review the limited literature pertaining to the potential for ctDNA technologies in such patients. Patients with these cancers stand to benefit greatly from the application of ctDNA technologies, and concerted efforts at further investigation of such are ongoing and greatly needed.",
keywords = "Cholangiocarcinoma, Circulating tumor DNA, Hepatocellular carcinoma, Liver neoplasms/blood, Liver neoplasms/genetics",
author = "Kabir Mody and Cleary, {Sean P.}",
year = "2018",
month = "6",
day = "11",
doi = "10.3389/fonc.2018.00212",
language = "English (US)",
volume = "8",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "JUN",

}

TY - JOUR

T1 - A review of circulating tumor DNA in hepatobiliary malignancies

AU - Mody, Kabir

AU - Cleary, Sean P.

PY - 2018/6/11

Y1 - 2018/6/11

N2 - Circulating tumor DNA (ctDNA) is released into circulation (blood) specifically from tumor cells undergoing metabolic secretion, apoptosis, or necrosis, carries tumor-specific genetic or epigenetic alterations. Technologies enabling clinical evaluation of ctDNA continue to advance rapidly and allow for the assessment of patient-specific tumoral genetic and epigenetic alterations. This holds great potential for earlier detection of disease, serial monitoring of tumor heterogeneity, identification of therapeutic targets, and evaluation of treatment response and mechanisms of resistance. Hepatobiliary malignancies are often diagnosed late, recur commonly, yield limited available tumor on biopsy, and harbor several genomic alterations with potential therapeutic impacts. Patients suffering from or at risk for these diseases thus stand to benefit immensely from this technology. Herein, we review the limited literature pertaining to the potential for ctDNA technologies in such patients. Patients with these cancers stand to benefit greatly from the application of ctDNA technologies, and concerted efforts at further investigation of such are ongoing and greatly needed.

AB - Circulating tumor DNA (ctDNA) is released into circulation (blood) specifically from tumor cells undergoing metabolic secretion, apoptosis, or necrosis, carries tumor-specific genetic or epigenetic alterations. Technologies enabling clinical evaluation of ctDNA continue to advance rapidly and allow for the assessment of patient-specific tumoral genetic and epigenetic alterations. This holds great potential for earlier detection of disease, serial monitoring of tumor heterogeneity, identification of therapeutic targets, and evaluation of treatment response and mechanisms of resistance. Hepatobiliary malignancies are often diagnosed late, recur commonly, yield limited available tumor on biopsy, and harbor several genomic alterations with potential therapeutic impacts. Patients suffering from or at risk for these diseases thus stand to benefit immensely from this technology. Herein, we review the limited literature pertaining to the potential for ctDNA technologies in such patients. Patients with these cancers stand to benefit greatly from the application of ctDNA technologies, and concerted efforts at further investigation of such are ongoing and greatly needed.

KW - Cholangiocarcinoma

KW - Circulating tumor DNA

KW - Hepatocellular carcinoma

KW - Liver neoplasms/blood

KW - Liver neoplasms/genetics

UR - http://www.scopus.com/inward/record.url?scp=85048629686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048629686&partnerID=8YFLogxK

U2 - 10.3389/fonc.2018.00212

DO - 10.3389/fonc.2018.00212

M3 - Review article

VL - 8

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - JUN

M1 - 212

ER -